MDxHealth, Inc. Receives 2011 European Molecular Diagnostics for Oncology Technology Leadership Award

Published: Jan 09, 2012

IRVINE, Calif. & LIEGE, Belgium--(BUSINESS WIRE)--Regulatory News:

MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, announced today the receipt of the Frost & Sullivan 2011 European Molecular Diagnostics for Oncology Technology Leadership award. In giving the awards, Frost & Sullivan recognizes the strength and broad applicability of MDxHealth’s epigenetic technology platform in generating advanced tests for cancer assessment and the personalized treatment of patients.

Back to news